Healthcare

Tenon Medical reports third-quarter 2026 results as revenue reaches $1.4 million

Tenon Medical reported higher third-quarter revenue and gross profit, raised approximately $15.6 million in gross proceeds, repaid its senior convertible notes and launched a 3D-printed lateral screw for its SImmetry®+ system.

Published:
Reading Time
4 min

Tenon Medical, Inc. (NASDAQ:TNON) reported third-quarter 2026 revenue of $1.4 million, up 22% from $1.2 million in the same quarter of 2025. The medical device company also disclosed financing activity, debt repayment, product development progress and additional patent awards for the period ended September 30, 2026.

#Revenue and profitability

Gross profit increased to $1.0 million from $0.8 million a year earlier. Gross margin was 66.3%, compared with 65.9% in the third quarter of 2025.

Tenon said the quarterly revenue increase was mainly related to a higher number of surgical procedures, including continued adoption of the SImmetry®+ SI Joint Fusion System. Revenue for the nine months ended September 30, 2026 was $4.1 million, compared with $2.5 million in the corresponding period of 2025.

Operating expenses were $4.0 million, down from $4.2 million in the prior-year quarter. The company attributed the reduction primarily to lower general and administrative costs and professional service fees. This was partly offset by higher sales and marketing expenses linked to revenue activity and increased research and development spending.

Operating loss improved to $3.1 million from $3.4 million. Net loss, however, was $6.6 million, or $5.39 per share, compared with $3.3 million, or $14.17 per share, in the third quarter of 2025.

Tenon said the higher net loss primarily reflected non-cash items below operating income, including $3.1 million related to warrants issued as inducement consideration and $0.7 million in non-cash interest expense from the amortisation of debt discount on convertible notes.

#Financing and debt repayment

The company raised approximately $15.6 million in aggregate gross proceeds during the third quarter. The proceeds included a $4.2 million public offering completed on July 1, 2026, a $3.0 million private placement closed on August 31, 2026, and a September 2026 warrant inducement transaction that generated approximately $2.9 million.

Tenon also received approximately $2.8 million from its at-the-market offering programme and approximately $2.7 million from warrant exercises during the quarter.

Cash and cash equivalents stood at $8.3 million as of September 30, 2026, compared with $3.8 million as of December 31, 2025. The company said it repaid its senior convertible notes in full through prepayments made in August and September 2026. The notes had an aggregate principal amount of approximately $5.16 million and were due to mature on September 11, 2026.

Tenon said it had no outstanding debt at the end of the quarter. It also reported regaining compliance with Nasdaq’s minimum stockholders’ equity requirement and minimum bid price requirement. The latter followed a 1-for-35 reverse stock split that took effect on August 10, 2026.

#Product and commercial updates

During the quarter, Tenon began the full commercial launch of a 3D-printed lateral screw for its SImmetry®+ SI Joint Fusion System. The company described the device as the first component of a next-generation lateral system.

The launch followed an alpha programme that generated approximately $1.2 million in revenue from late in the fourth quarter of 2025 through the third quarter of 2026.

Tenon also said it had completed the initial alpha cases of its Quickstep™ Decorticator. The device is intended to streamline joint decortication and simplify the SImmetry®+ surgical workflow. The company is targeting full market release in the first quarter of 2027, although that timing remains a company target.

Thomas Batton Jr. joined Tenon as chief revenue officer effective October 1, 2026. The company said it plans to continue expanding its commercial organisation through direct sales representatives and distributor partners.

#Patent portfolio

The U.S. Patent and Trademark Office issued eight new patents to Tenon during 2026, bringing the company’s portfolio to 38 issued U.S. patents. Tenon also reported nine international patents and 31 U.S. and foreign patent applications pending.

The new patents include system and method claims covering the Catamaran® SI Joint Fusion System, according to the company.

#Risks and stated priorities

For the balance of 2026, President and CEO Steven M. Foster said Tenon’s priorities are expanding physician training and adoption across both platforms, advancing the product pipeline and maintaining discipline on spending.

Tenon cautioned that its forward-looking statements are uncertain and that actual results may differ materially from its assumptions, estimates or expectations. The company identified a need to raise additional capital and substantial doubt about its ability to continue as a going concern among the factors that could affect future outcomes.

#Key Takeaways

  • Third-quarter 2026 revenue was $1.4 million, while gross profit was $1.0 million and gross margin was 66.3%.
  • Tenon raised approximately $15.6 million in aggregate gross proceeds and ended the quarter with $8.3 million in cash and cash equivalents.
  • The company repaid senior convertible notes with an aggregate principal amount of approximately $5.16 million and reported no outstanding debt at quarter-end.
  • Tenon commercially launched a 3D-printed lateral screw for the SImmetry®+ system and completed initial alpha cases of its Quickstep™ Decorticator.
  • The company reported eight new U.S. patents in 2026, bringing its portfolio to 38 issued U.S. patents, while also disclosing the need for additional capital and substantial doubt about its ability to continue as a going concern.

Original source: Read original article

Frequently Asked Questions